Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera <sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trialYuankai Shi, Yanan Ji, Yuhuan Gao et al.|Hematological Oncology|2022Cited by 9
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphomaXiaohong Han, Yuankai Shi, Mingzhi Zhang et al.|Chinese Journal of Cancer Research|2022Cited by 5